AZ-1355

• Description :

  AZ-1355 is an orally active and effctive lipid-lowering agent. AZ-1355 inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro[1].

• UNSPSC :

  12352005

• Target :

  Prostaglandin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Endocrinology; Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/AZ-1355.html

• Purity :

  98.19

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=CC=C2OC3=C(OC)C=CC=C3CNC2=C1)OCC

• Molecular Formula :

  C17H17NO4

• Molecular Weight :

  299.32

• References & Citations :

  [1]Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40 (3-4) :263-71.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  IP; TXA2/TP

• CAS Number :

  [75451-07-9]